Status:

COMPLETED

Improving Transplant Medication Safety Through A Technology and Pharmacist Intervention

Lead Sponsor:

VA Office of Research and Development

Conditions:

Transplant

Eligibility:

All Genders

Phase:

NA

Brief Summary

Medication safety issues in Veteran organ transplant recipients, including side effects and errors, are a major issue leading to graft failure and death. The causes of these events are complicated and...

Detailed Description

Anticipated Impacts on Veterans Health Care: The first three essential strategies listed within the VA's Blueprint for Excellence encompass plans to improve care to vulnerable Veterans, deliver high q...

Eligibility Criteria

Inclusion

  • Veteran organ transplant recipients will be identified using International Classification of Diseases (ICD) 9/10 codes from the VA electronic health record (CPRS).
  • Patients must have an active code stating they are a recipient of an organ transplant.
  • The following codes will be utilized - ICD-9 codes:
  • V42.0
  • V42.1
  • V42.6
  • V42.7
  • V42.83
  • V42.84
  • 81
  • 82
  • 83
  • 84
  • 86
  • 80
  • OR
  • oICD-10 codes:
  • C80.2
  • T86.1
  • T86.10
  • T86.11
  • T86.12
  • T86.13
  • T86.19
  • T86.2
  • T86.20
  • T86.21
  • T86.22
  • T86.23
  • T86.290
  • T86.298
  • T86.3
  • T86.30
  • T86.31
  • T86.32
  • T86.33
  • T86.39
  • T86.4
  • T86.40
  • T86.41
  • T86.42
  • T86.43
  • T86.49
  • T86.810
  • T86.811
  • T86.812
  • T86.818
  • T86.819
  • T86.9
  • Z48.2
  • Z48.21
  • Z48.22
  • Z48.23
  • Z48.24
  • Z48.280
  • Z48.288
  • Z48.298
  • Z94.0
  • Z94.1
  • Z94.2
  • Z94.3
  • Z94.4
  • Z94.83
  • AND
  • Actively receiving at least one anti-rejection medication dispensed by the VA site.
  • These medications include:
  • tacrolimus
  • cyclosporine
  • azathioprine
  • mycophenolate
  • sirolimus
  • everolimus
  • belatacept

Exclusion

  • There are no exclusion criteria for patients in this study as recruitment is at the level of the VA site.
  • All veterans meeting inclusion criteria will be monitored by the dashboard system and will be included in the outcomes assessment.
  • Patients may enter or exit the study in a rolling manner, which will be accounted for during analyses.

Key Trial Info

Start Date :

March 18 2019

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

June 14 2021

Estimated Enrollment :

2196 Patients enrolled

Trial Details

Trial ID

NCT03860818

Start Date

March 18 2019

End Date

June 14 2021

Last Update

August 1 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Ralph H. Johnson VA Medical Center, Charleston, SC

Charleston, South Carolina, United States, 29401-5799

Improving Transplant Medication Safety Through A Technology and Pharmacist Intervention | DecenTrialz